| Literature DB >> 10699539 |
S Kornblau1, A B Benson, R Catalano, R E Champlin, C Engelking, M Field, C Ippoliti, H M Lazarus, E Mitchell, J Rubin, P J Stiff, E Vokes, S Wadler.
Abstract
The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10699539 DOI： 10.1016/s0885-3924(99)00149-9
Source DB: PubMed Journal: J Pain Symptom Manage ISSN： 0885-3924 Impact factor: 3.612